Selected article for: "acute kidney injury aki and logistic regression analysis"
Author: Campos-Murguía, Alejandro; Román-Calleja, Berenice Monserrat; Toledo-Coronado, Israel Vicente; González-Regueiro, José Alberto; Solís-Ortega, Alberto Adrián; Kúsulas-Delint, Deyanira; Cruz-Contreras, Mariana; Cruz-Yedra, Nabila; Cubero, Francisco Javier; Nevzorova, Yulia Alexandrowna; Martínez-Cabrera, Carlos Fernando; Moreno-Guillén, Paulina; Lozano-Cruz, Oscar Arturo; Chapa-Ibargüengoitia, Mónica; Gulías-Herrero, Alfonso; Aguilar-Salinas, Carlos Alberto; Ruiz-Margáin, Astrid; Macías-Rodríguez, Ricardo Ulises
Title: Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
  • Cord-id: g592gmjx
  • Document date: 2021_2_2
    • ID: g592gmjx
    Snippet: BACKGROUND: Metabolic diseases are risk factors for severe Coronavirus disease (COVID-19), which have a close relationship with metabolic dysfunction-associated fatty liver disease (MAFLD). AIMS: To evaluate the presence of MAFLD and fibrosis in patients with COVID-19 and its association with prognosis. METHODS: Retrospective cohort study. In hospitalized patients with COVID-19, the presence of liver steatosis was determined by computed tomography scan (CT). Liver fibrosis was assessed using the
    Document: BACKGROUND: Metabolic diseases are risk factors for severe Coronavirus disease (COVID-19), which have a close relationship with metabolic dysfunction-associated fatty liver disease (MAFLD). AIMS: To evaluate the presence of MAFLD and fibrosis in patients with COVID-19 and its association with prognosis. METHODS: Retrospective cohort study. In hospitalized patients with COVID-19, the presence of liver steatosis was determined by computed tomography scan (CT). Liver fibrosis was assessed using the NAFLD fibrosis score (NFS score), and when altered, the AST to platelet ratio index (APRI) score. Mann-Whitney U, Student´s t-test, logistic regression analysis, Kaplan-Meier curves and Cox regression analysis were used. RESULTS: 432 patients were analyzed, finding steatosis in 40.6%. No differences in pulmonary involvement on CT scan, treatment, or number of days between the onset of symptoms and hospital admission were found between patients with and without MAFLD. The presence of liver fibrosis was associated with higher severity scores, higher levels of inflammatory markers, requirement of mechanical ventilation, incidence of acute kidney injury (AKI), and higher mortality than patients without fibrosis. CONCLUSION: The presence of fibrosis rather than the presence of MAFLD is associated with increased risk for mechanical ventilation, development of AKI, and higher mortality in COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • abnormal liver test and liver describe: 1
    • abnormal liver test and liver disease: 1, 2, 3, 4, 5, 6
    • absence presence and absolute frequency: 1
    • absence presence and activation inflammation: 1, 2
    • absence presence and acute aki kidney injury: 1, 2, 3
    • absence presence and acute kidney injury: 1, 2, 3, 4, 5, 6, 7
    • absence presence and additional study: 1, 2, 3, 4
    • absence presence and adequate diagnosis: 1, 2
    • absence presence and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activation inflammation and acute aki kidney injury: 1, 2, 3, 4, 5
    • activation inflammation and acute kidney injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activation inflammation and liver disease: 1, 2
    • acute aki kidney injury and additional study: 1
    • acute aki kidney injury and adequate diagnosis: 1
    • acute aki kidney injury and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute aki kidney injury and liver disease main cause: 1
    • acute aki kidney injury high incidence and liver disease: 1, 2
    • acute kidney injury and liver disease implication: 1
    • acute kidney injury and liver disease main cause: 1